Verve Therapeutics

Phase A — Understand the business

Lens 1 · Company Overview

Verve Therapeutics is a clinical-stage genetic-medicines company built on one contrarian bet: that the biggest cardiovascular killers — high LDL cholesterol, high Lp(a) — should be treated once, permanently, by editing a gene in the liver, not managed for life with daily pills and biannual injections. Incorporated 2018 (originally "Endcadia, Inc."), HQ at 201 Brookline Avenue, Boston; IPO'd on Nasdaq (VERV) on 2021-06-17.

Business model: there is no product revenue. The "product" is a pipeline of in vivo base-editing / gene-editing candidates plus the proprietary GalNAc-LNP liver-targeting delivery system. Cash came from equity, and from two structured pharma collaborations with Eli Lilly (see Lens 2) that de-risked the balance sheet and, ultimately, set up the buyer.

Lead programs (the asset table is the company):

• VERVE-102 — adenine base editor targeting PCSK9 (turns the gene off in hepatocytes to durably lower LDL-C); GalNAc-LNP delivery; in the Heart-2 Phase 1b trial.
• VERVE-201 — targets ANGPTL3 for refractory hypercholesterolemia; Pulse-1 Phase 1b.
• VERVE-301 — targets LPA / Lp(a); development candidate named Jan 2025; the asset inside the broader Lilly research collaboration.
• VERVE-101 — the original PCSK9 candidate (Heart-1), deprioritized after a 2024 safety signal (see Lens 8/10); -102 is the successor with an improved GalNAc-LNP.

Customers / payers: none yet — pre-commercial. The economic "customers" today are its collaboration counterparties (Lilly; previously Vertex). End-market at commercialization would be the ~tens of millions of high-cardiovascular-risk / familial-hypercholesterolemia / established-ASCVD patients, a market anchored by the existing PCSK9 franchise (Amgen's Repatha, Regeneron/Sanofi's Praluent, Novartis's Leqvio) — Verve's pitch is "one-and-done" vs. their chronic dosing.

Lens 2 · Supply Chain

Map: IP/delivery inputs → Verve (editor design + GalNAc-LNP) → CMOs (manufacture) → clinical sites → (intended) Lilly commercial engine → patients. Every named stakeholder I can source:

• Base-editing IP / co-founder — Beam Therapeutics. Verve's base-editing rights trace to Beam (both are David Liu-lab lineage). The Amended & Restated Collaboration and License Agreement (ARCLA) with Beam governs the PCSK9 base-editor rights — and is the very instrument Lilly bought into (Lilly acquired Beam's opt-in right).
• LNP delivery IP — Acuitas Therapeutics. Verve licenses lipid-nanoparticle technology from Acuitas; the Acuitas Development Agreement is "a component of our VERVE-101 product candidate," and Verve owes Acuitas milestone payments. This is a genuine single-source dependency on the delivery layer.
• Former collaborator — Vertex. Vertex was a collaboration partner (a Vertex executive joined Verve's board June 2024); Vertex terminated its agreement for convenience in Jan 2025 (effective Apr 2025), which forced Verve to recognize the $20.0M remaining deferred revenue in Q1-2025. A churned counterparty, now closed out.
• Manufacturing — third-party CMOs / CROs. mRNA, guide RNA, and LNP fill-finish are outsourced; Q1-2025 R&D growth was partly "raw material costs and external expenses… including third-party CMOs" and "animal-study costs… third-party CROs". No in-house commercial-scale manufacturing — a normal chokepoint for a Phase-1 biotech.
• Acquirer / commercial engine — Eli Lilly. Pre-deal, Lilly was the opt-in/commercialization partner for PCSK9 (via the ARCLA) and the exclusive partner for the Lp(a) program; post-July-2025, Lilly owns the whole chain. The "end customer" of the corporate entity turned out to be Lilly itself.

Chokepoints: (1) Acuitas LNP license — single-source delivery IP; (2) CMO capacity for clinical supply; (3) the base-editing IP estate shared with Beam (and the dynamic genome-editing patent landscape generally — see Lens 10).

Lens 3 · Competitive Advantages (moats)

For a pre-revenue editor, "moat" = science + IP + a delivery edge + data, not brand or scale.

• Delivery is the real edge. The entire field's bottleneck is getting an editor into the right tissue safely. Verve's GalNAc-LNP is engineered to home to hepatocytes via the asialoglycoprotein receptor, and the VERVE-102 data (clean safety + deep PCSK9/LDL-C knockdown, below) is the proof that the redesigned LNP fixed the -101 problem. Liver is the "easy" organ — but doing it durably and safely at clinical dose is not trivial, and Verve demonstrably did.
• A genetically validated target set. PCSK9, ANGPTL3, and LPA are among the most human-genetics-validated cardiovascular targets in existence (loss-of-function carriers have low LDL/Lp(a) and lower heart-disease risk with no obvious downside) — founder Sekar Kathiresan's own field. This de-risks biology, not execution.
• One-and-done vs. chronic dosing — a structural product advantage if durability and safety hold across a large CV-outcomes program. A single infusion that permanently lowers LDL-C reframes adherence (the Achilles' heel of every chronic lipid therapy).
• IP / bargaining power — mixed. Verve sits downstream of Beam (base-editing) and Acuitas (LNP); it does not own the foundational platforms outright, so its bargaining power over those suppliers is limited (it pays milestones/royalties up the stack). Its leverage over a buyer turned out to be the data: the VERVE-102 readout is precisely what let Lilly pay a 113% premium.
• Bargaining power over customers: n/a (no customers; pre-commercial).

Verdict: the moat is a credible delivery-plus-data lead in liver base-editing — strong enough to attract a $1.3B takeout, but not a self-sufficient platform Verve owned end-to-end. That dependency is exactly why being acquired (rather than going it alone) was rational.

Lens 4 · Segments

No reportable product or geographic segments — single development-stage entity, no commercial revenue. The only "revenue" Verve booked was collaboration revenue (reimbursements + the $20.0M Vertex deferred-revenue catch-up in Q1-2025). Reported strictly as one segment. The economically meaningful "segmentation" is by program — PCSK9 (VERVE-102, lead) / ANGPTL3 (VERVE-201) / Lp(a) (VERVE-301) — which is captured in Lens 5.

---

Phase B — Measure performance (clinical overlay: pipeline-by-phase, catalyst calendar, rNPV/CVR)

Lens 5 · Pipeline by Phase (replaces "Earnings Result")

The asset table is the company. Status as of the last filing on disk + the final Heart-2 data from the web:

The key financial print (Q1-2025, the last filed quarter):

• Net loss $31.0M (vs. $48.7M in Q1-2024) — but the improvement is flattered by the one-time $20.0M Vertex deferred-revenue recognition; on an operating basis spend rose.
• R&D $54.5M (Q1-2025) vs. $48.4M (Q1-2024), +$6.1M — more headcount, Heart-2 + Pulse-1 trial costs, CMO/CRO spend.
• G&A $15.2M vs. ~$14M prior year.
• Cash + marketable securities $497.1M (2025-03-31); accumulated deficit $774.0M.
• FY2024 (10-K): R&D $204M, G&A $56M, net loss ~$198.7M, cash $524.3M (YE2024), accumulated deficit $743.0M.
• Guided runway: into mid-2027 on the standalone balance sheet. Runway comfortably reached the value-inflection catalyst (Heart-2 final data / Phase 2 start) — which is what made the company sellable from a position of strength rather than distress.

Lens 7 · Catalyst Calendar + Mechanism Comps (replaces "Comps")

Catalyst calendar (what de-risks or kills each program):

• 2H-2025: Heart-2 final dose-escalation data; first patient dosed in VERVE-102 Phase 2; Lilly PCSK9 opt-in decision — all hit/superseded by the acquisition.
• The live one (post-deal): the CVR trigger — first patient dosed with VERVE-102 in a US Phase 3 for ASCVD, on or before the 10th anniversary of closing. This is the only remaining scoreable catalyst for CVR holders.
• VERVE-201 (ANGPTL3) Pulse-1 readouts; VERVE-301 (Lp(a)) IND — now on Lilly's internal clock, not publicly catalyst-driven.

Mechanism comps (by target/modality, not P/E — these are pre-revenue editors):

Lens 8 · Stock-Price Catalysts (>5% moves, last ~5 years)

The tape tells the whole story of a binary-driven biotech:

• 2021-09-10: all-time high close ~$73.99 — peak gene-editing exuberance.
• 2021–2023 drawdown: rates + biotech bear + the long pre-data grind; an IPO buyer was down ~86% by 2025 (≈ −39% CAGR over 4 years).
• 2024-04 (the big one): Heart-1 pause. VERVE-101's 6th patient at 0.45 mg/kg had a Grade 3 transient ALT increase + Grade 3 thrombocytopenia → enrollment halted, pivot to VERVE-102 → sharp selloff and a securities class action. The single most important negative catalyst in the company's life.
• 2024–2025: VERVE-102 redemption. Heart-2 data showing deep, durable, clean PCSK9/LDL-C knockdown rebuilt the thesis — the proof the delivery problem was solved.
• 2025-06-17 (terminal catalyst): Lilly bid. +~113% premium to 30-day VWAP; shares re-rated to ~$11.12, above the $10.50 cash floor, implying the market assigned ~21% probability to the $3 CVR paying.

Pattern the market reacts to: for Verve it was clinical safety/efficacy binaries on the lead PCSK9 asset — not earnings (there are none), not macro. Safety risk (an off-target/LNP tolerability event) is the variable that moves this name most; a deep, clean knockdown is the upside catalyst. Classic single-asset, single-mechanism biotech tape.

---

Phase C — Judge people & books

Lens 9 · Management

• Sekar Kathiresan, MD — Co-founder & CEO. A genuine founder-scientist: cardiologist/human-geneticist, former Director of the Cardiovascular Disease Initiative at the Broad Institute, whose own research established the human loss-of-function genetics (PCSK9, ANGPTL3, LPA) that Verve is built to drug. Personal motivation (heart attacks in his own family) is well-documented — a credible, mission-driven founder rather than a serial operator. Archetype: scientist-founder, appropriate for a discovery-stage platform; the open question (now moot) was always whether he'd hand off to a commercial operator at the launch stage. Selling to Lilly resolved that — the asset goes to the best-capitalized cardiometabolic commercial machine on earth.
• Andrew Bellinger, MD PhD — Chief Scientific Officer (cardiologist-scientist).
• Track record: got two distinct programs into the clinic, generated best-in-class-looking PCSK9 base-editing data, recovered from a serious mid-stage safety setback (Heart-1) by re-engineering the delivery vehicle, and monetized at a 113% premium. For a clinical-stage CEO, that is a strong scorecard.
• Skin in the game / insider ownership: n/a — insider-transactions.csv not present; founder equity meaningful but unquantified here.
• Capital allocation: disciplined — kept runway to mid-2027, used structured Lilly collaborations to fund programs without dilutive raises at the lows, and sold from strength. The Vertex relationship churned (terminated for convenience) but was cleanly closed out.
• Red flags: the Heart-1 pause spawned the Oldroyd securities suit (Lens 10) — dismissed; no related-party or comp red flags surfaced in the filings beyond ordinary collaboration economics.

Lens 10 · Forensic Red Flags

Pre-revenue biotech → the forensic surface is cash burn, going-concern, dilution, and trial-design integrity, not revenue-recognition games. Findings:

• Revenue recognition (what there is): the only revenue is collaboration reimbursement; the $20.0M Vertex deferred-revenue acceleration in Q1-2025 is a one-timer that makes the YoY net-loss improvement look better than the underlying cash burn — don't read $31.0M net loss as a run-rate. Honestly disclosed, but a place a careless reader gets fooled.
• Cash burn vs. earnings: net loss ~$198.7M FY2024; the cash-flow statement reconciles net loss adjusted for non-cash items (SBC). Burn is real and large relative to the $497–524M cash pile — hence the mid-2027 runway and the strategic logic of a sale.
• SBC / dilution: stock-based comp is a material non-cash add-back (standard for the sector); share count grows via equity programs and the prior Lilly equity purchases (Lilly bought stock at $19 and at $10 under the collaboration). Dilution risk is now moot post-takeout.
• Going concern: management asserted cash "sufficient to fund operations and capital expenditure requirements beyond the next 12 months" — no going-concern qualifier.
• Trial-design / safety integrity (the real risk): the Heart-1 Grade-3 ALT/thrombocytopenia event is the substantive forensic item — it was disclosed, drove the -101→-102 pivot, and the redesigned program produced clean data. Off-target editing and LNP tolerability remain the structural scientific risks of the modality.

Regulatory findings (required sub-section):

• SEC Litigation Releases / AAERs: none. total_sec_findings: 0 — no LR, no AAER naming Verve in 2021-06-20→2026-06-20.
• Item 3 Legal Proceedings (10-K, the company's own disclosure): "As of the date of this Annual Report… we were not party to any material legal matters or claims." It then discloses Oldroyd v. Verve Therapeutics (Case No. 1:24-CV-12218, D. Mass., filed 2024-08-27) — a putative securities class action under §10(b)/§20(a)/Rule 10b-5 alleging misleading statements about the Heart-1 enrollment pause. Lead plaintiff appointed Dec-2024; voluntarily dismissed without prejudice 2025-02-04. Resolved — not an overhang.
• Non-SEC enforcement (FTC/DOJ/FDA, web): no enforcement actions, consent decrees, fines, or penalties found. The only regulator interaction of note is positive: FTC granted early termination of the HSR waiting period for the Lilly deal on 2025-07-22 — i.e., antitrust cleared, not contested.
• Conclusion: No material adverse regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER → 0), 10-K Item 3 (one securities suit, dismissed), and web search (no agency actions; HSR cleared) as of 2026-06-20.

---

Phase D — Project & stress-test

Lens 11 · rNPV / CVR Valuation (replaces "Forward Projection"; runway-to-catalyst)

EPS projection is not the right object — Verve was bought; there is no standalone P&L going forward. The decision-relevant valuation is the CVR.

The CVR, valued explicitly:

• Payoff: $3.00/share, paid once the first patient is dosed in a US Phase 3 of VERVE-102 for ASCVD, before the 10th anniversary of closing.
• Undiscounted expected value = $3.00 × P(milestone within 10y).
• Market-implied probability: with shares trading ~$11.12 against a $10.50 cash floor, the market paid ~$0.62 for the CVR → P ≈ 0.62 / 3.00 ≈ 21% (ignoring discounting; the true risk-neutral probability is a bit higher once you discount the payment).
• Present value of a certain $3.00: ~$1.75 at a 5% discount over the full window — so even the bulls' ceiling, probability-weighted, is well under $3.00.
• Sell-side spread: William Blair (Minter) called $10.50 a "bargain" vs. a $30.86 pre-deal fair value; BMO (Biliouris) was skeptical on commercial need but still assigned ~70% probability to the CVR payout. The 21% market-implied vs. 70% one-analyst gap is the trade for any CVR holder.

My base case on the CVR: VERVE-102's Phase 1b data is strong and Lilly clearly intends to advance it — but a US Phase 3 ASCVD dosing is a multi-year path (Phase 2 → outcomes-trial design → first dosing) with real attrition (a single durability or safety wobble defers or kills it). A ~30–45% realized probability feels more honest than the market's 21% or BMO's 70%; that pins fair CVR value around $0.90–$1.35 undiscounted (~$0.75–$1.10 PV). The CVR is modestly underpriced by the tape but nowhere near a sure thing — a coin-flip-ish milestone dressed as a lottery ticket.

(No Brier forecast logged — forecast.ts create is skipped in the watchlist loop per the SKILL; and the natural binary here, "VERVE-102 reaches US Phase 3 dosing," is a Lilly-internal decade-long clock, not a near-term scoreable readout.)

Lens 12 · Bull vs Bear

Bull (why Lilly paid up, and why the CVR can pay): PCSK9 is the most validated lipid target in medicine; VERVE-102 showed best-in-class-looking, durable LDL-C lowering with a clean safety profile — the proof that liver base-editing works in humans and that the redesigned GalNAc-LNP fixed the -101 problem. "One infusion, lifelong LDL control" is a genuinely category-defining product if a CV-outcomes trial confirms it, and Lilly is the single best owner to fund a massive cardiometabolic outcomes program. The deal itself validated the entire base-editing modality.

Bear / pre-mortem (it's 18 months out and the CVR is trending to zero — what happened?): Phase 2 surfaces a durability fade (editing is permanent, but PCSK9 protein creeps back) or a delayed-tolerability / off-target signal that the small Phase 1b couldn't see; Lilly, awash in GLP-1 cash and with Lp(a)/PCSK9 small-molecule and siRNA alternatives, slow-walks the program or reprioritizes; the Phase 3 dosing milestone slips past a practical horizon and the CVR's PV bleeds toward zero. The structural skeptic case (BMO): the world may not need another genetic medicine in lipids when Leqvio (siRNA, twice-yearly) and oral PCSK9 inhibitors already exist and are cheaper to develop.

Are multiples too high? Inapplicable — closed deal at a 113% premium; the only "multiple" left is the CVR's implied probability, which (per Lens 11) the tape arguably under-prices.

Contrarian view of what the market refuses to see: the read-through, not Verve itself. The market is treating the Verve CVR as a niche special-situation; the real signal is that big pharma will pay up-front for de-risked liver base-editing — which reprices takeout optionality across Beam especially (same modality, same lineage, deeper cash) and the in-vivo editing cohort broadly. The dead stock is a live datapoint about its peers.

Lens 13 · Devil's Advocate (short-seller)

If I'm dismantling the bull case on the CVR:

• Revenue concentration → milestone concentration. The entire residual value rides on one asset (VERVE-102) hitting one milestone (US Phase 3 dosing) on a 10-year clock controlled by an acquirer with no obligation to hurry. That is maximal single-point-of-failure risk.
• The moat was rented, not owned. Verve sat downstream of Beam (base-editing IP) and Acuitas (LNP) — the genome-editing patent landscape is "highly dynamic" and litigation-prone by the company's own admission. An IP dispute up the stack could entangle the program.
• Safety is the recurring ghost. The modality already produced one serious clinical safety event (Heart-1). Base editing is irreversible; a delayed off-target or immunogenicity signal in a larger, longer Phase 2/3 is the scenario that permanently impairs the asset — and there is no "stop the daily pill" off-ramp once a patient is edited.
• Most dangerous competitor bulls underestimate: incumbent chronic lipid therapy that's "good enough." Leqvio (twice-yearly siRNA) and emerging oral PCSK9 inhibitors deliver most of the LDL benefit with reversibility and far cheaper development — undercutting the "one-and-done premium." Plus Lilly's own internal cardiometabolic priorities (GLP-1 franchise) compete for the capital that would fund Verve's Phase 3.
• What must hold for the CVR to pay: durability proven over years, no new safety signal, Lilly commits the capital, and the milestone is reached inside the window. Stack those conditional probabilities and the market's ~21% looks less like pessimism and more like arithmetic.
• If growth/data disappoints 20–30%: for a CVR there's no partial credit — the milestone is binary. A meaningful Phase 2 disappointment doesn't haircut the value, it likely zeroes the CVR.

Lens 14 · Management Questions (now effectively for Lilly's cardiometabolic leadership — ordered by information value)

1. What is the expected timeline to first patient dosed in a US Phase 3 of VERVE-102 for ASCVD — and what specifically must Phase 2 show to greenlight it? (This is the CVR.)
2. How durable is the PCSK9/LDL-C knockdown at the longest follow-up now available, and is there any evidence of protein rebound over time?
3. Have you seen any delayed safety signal (hepatic, hematologic, immunologic, off-target editing) beyond the early window in the larger dataset?
4. Given Lilly's GLP-1 / oral cardiometabolic priorities, where does VERVE-102 actually rank for capital and trial-site allocation over the next 3 years?
5. How does VERVE-102's value proposition hold up against twice-yearly siRNA (Leqvio) and oral PCSK9 inhibitors on a payer/cost-effectiveness basis?
6. What is the regulatory path and CV-outcomes-trial design you'll need for approval, and how large/long is it?
7. What is the status and read-through of VERVE-201 (ANGPTL3) and VERVE-301 (Lp(a)) now inside Lilly — advancing, partnered, or shelved?
8. How exposed is the program to the Beam / Acuitas IP stack, and are any patent disputes outstanding or anticipated?
9. What manufacturing / CMO scale-up is required to support a Phase 3 and eventual launch, and is LNP supply a constraint?
10. What is the target patient population and pricing model for a one-time gene-editing lipid therapy — and how do you underwrite reimbursement for a single large upfront cost?
11. What off-target / long-term genotoxicity monitoring commitments will regulators require for an irreversible liver edit?
12. How will you handle manufacturing comparability as you move from clinical to commercial GalNAc-LNP supply?
13. What is the competitive CV-outcomes timeline vs. any rival in-vivo editing or next-gen lipid programs?
14. Which biomarker (Lp(a), ApoB, LDL-C) anchors the registrational endpoint, and is there regulatory alignment on it?
15. What would make Lilly walk away from the VERVE-102 Phase 3 — i.e., what kills the CVR from your side?

---